Marc R. Shepard M.D.
5122 Strathmore Ave
Rockville, MD 20852



Northwestern University Medical School
Chicago, Illinois
Doctor of Medicine, 1978

University of Michigan
School of Literature, Science and Arts
Ann Arbor, MI
Bachelor of Science, Magna Cum Laude, 1974


George Washington University Hospital, Washington, DC 1979 - 1981
Residency, Internal Medicine and Primary Care

George Washington University Hospital, Washington, DC 1978 - 1979

Professional Experience

Jeanne Jugan Nursing Home, Staff Physician 1982-present
Medical Director 2011-present

Expert Witness 2002-present review cases, plaintiff and defense as expert witness in Internal Medicine, Long term Care

Medstar Physician Group January 1, 2012-December 2019 Medstar Health Research Institute January 1, 2012-December, 2019

Private Practice, General Internal Medicine 1982-2011
Shepard and Lugerner, M.D., Inc.
Washington, DC

George Washington University, Associate Professor 1981-2012
Teaching medical students in office
Physical Diagnosis class

Providence Hospital, Part-time Faculty 1982-1999

Washington Nursing Facility, Staff Physician 1982-1988

Rock Creek Manor Nursing Home, Staff Physician 1986-2011 Medical Director , 1994 -2011

Delmarva (PRO for Medicare), Physician Advisor 1985-2014 Utilization Review Concurrent, Post hospitalization, Outpatient Utilization review, Peer Review in Medicare PRO

DCIPA, Vice President 1986-1991, executive officer in physician owned company providing managed care services

NYLCare, Regional Medical Director

Peer Review, Pharmacy and Therapeutics Committee Chair, Credentialing Committee, Utilization Review Committee 1991-1998

George Washington University Health Plan, Staff Physician 1981-1982

nTouch Research, Principal Investigator 1998-2004

Accelovance, Principal Investigator January, 2005 – 2011

Millennium Clinical Research Center L.L.C., Investigator 2000-2005

Forensic Medical Advisory Services, 2005-2009. Malpractice review of cases

Licensure and Certification

District of Columbia
Internal Medicine, Diplomate 1981


American College of Physicians


Fellow American College Physicians July, 2013

Medstar Physician of the Year April, 2017

Washingtonian Best Doctors 2017

Washingtonian Best Doctors 2018

Washingtonian Best Doctors 2019

Clinical Trial Experience:

KOWA Phase 3 hypertriglyceridemia in diabetic patients

H9X-MC-GBGL Phase 3 trial dulaglutide in diabetes

TIMI Phase 4 trial locaserin in high risk diabetic patients

Devote 4080 Phase 4 Novo Nordisk Lantus vs degludec safety trial 2014-2018

Phase 3 trial Boeringer Ingelheim 1245.25, diabetes with cardiovascular disease, 2011-2017

Phase 4 trial of Embeda for chronic pain, 2011

A phase 3 randomized double blind hypertension trial using ambulatory blood pressure monitoring TAK 491-010 2008

A phase 3 randomized hypertension trial using abpm TAK491-301 2007-2008

A randomized trial testing bird flu vaccine in healthy subjects AVEC/rYP/03-QUI211 Avecia, 2007

 Jupiter: A trial to study patients with elevated CRP and normal cholesterol. Astra-Zeneca, 2003-2007

A randomized, double-Blind Study Evaluating the Safety and Tolerability of a 600-mg XXXXX and a 600-mg XXXXX of Oral XXXXX Oral Placebo for 14 Days in Volunteers.(SAL001) 2006

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of XXXXX When Used in Combination with XXXXX in Subjects with Type 2 Diabetes. (PPD254) 2006

A Prospective, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of the 28-day Oral Contraceptive XXXXX. (DMP002) 2006

A phase IIIb, prospective, double-blind, randomized, controlled multicenter study to evaluate immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed XXXXX compared to Sanof Pasteur's tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed XXXXX, when administered as a booster vaccination in adults aged 19 to 64 years of age. (GSK068) 2006

A Multicenter, Randomized, Double-Blind, Parallel-Group study to evaluate the efficacy and safety of the combination of XXXXX compared to XXXXX, and XXXXX in patients with moderate to severe hypertension. (NVR044) 2006

A Double-Blind, Randomized, Placebo Controlled Factorial Study to Evaluate the Efficacy and Safety of TAK-475 and XXXXX Alone and in Combination in Subjects with Hypercholesterolemia. (MDS011) 2006

A Phase 1, parallel group, single blind study to evaluate the safety, tolerability and immunogenicity of a recombinant plague vaccine XXXXX in healthy subjects. (QUI211) 2005

A multicenter, partially blind, parallel-group, controlled study of the safety and immunogenicity of XXXXX vaccine compared with XXXXX in a healthy population Phase II Anthrax vaccine study. (QUI191) 2005

Jupiter, a national randomized, placebo controlled study to determine the benefits of a statin drug in patients with elevated C reactive protein, normal serum cholesterol

Clinical Utility of XXXXX in Simultaneously Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population (CAPABLE). (QUI183) 2004

Study of XXXXX in Women of Different Demographic Characteristics and Co-morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety. (OMI008) 2004

A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of XXXXX (320mg) and XXXXX (12.5 and 25mg) combined and alone, XXXXX 160mg and XXXXX 160mg/hydrochlorothiazide 12.5mg in hypertensive patients. (NVR022) 2004 Extended Use of XXXXX in Constipated Patients. (MTR021) 2004

Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy and Safety of XXXXX 10 mg daily vs. Placebo in Subjects Who Use XXXXX 180 mg daily to Treat Their Allergic Rhinitis Symptoms. (IVR015) 2004

A Multicenter, Randomized, Double-Blind, Prospective, Parallel Study to Compare the Safety and Efficacy of XXXXX or XXXXX as Add-On Therapy to XXXXX in Subjects with Combined Hyperlipidemia, Typical of the Metabolic Syndrome. (ABB011) 2004

An Open Label Study of Chronic XXXXX Use in Constipated Patients. (MTR012) 2003

A prospective, randomized, open-label, blinded end-point, forced-titration trial to compare XXXXX to XXXXX, for the control of mild-moderate hypertension in obese patients with type-2 diabetes mellitus using ambulatory blood pressure monitoring. (BIP013) 2003

Comparative Randomized Study Of Safety And Immunogenicity Of A XXXXX Versus An RSV Vaccine Adjuvanted With Alumimum Phosphate When Administered Concomitantly With A Licensed Influenza Vaccine In High-Risk Adults greater then 65 Years of Age. (PPD154) 2002
Clinical utility of XXXXX to improve concomitant cardiovascular risk factor of hypertension and dyslipidemia (Gemini). (QUI118) 2002

A Randomized, Open-Label, 3 Arm Parallel-group, Multicenter Phase IIIb Study Comparing the Efficacy & Safety of XXXXX with Atorvastatin and Simvastatin Achieving NCEP ATP III LDL-C Goals in High-Risk Subjects with Hypercholesterolemia in the Managed Care Setting. (IBA042) 2002

XXXXX vs. XXXXX as Add-on Therapy in Type 2 Diabetes Patients Failing Sulfonylurea and zzz Combination Treatment:

A Randomization, Open, Parallel Study (PPD150) 2002 A randomized, double-blind, multi-center, two-arm study to investigate the safety and tolerability of flexible doses of XXXXX or XXXXX given on demand in African American, Hispanic and Caucasian males with erectile dysfunction. (PRA046) 2002

A multicenter, randomized, open-label comparison of the effects of XXXXX and usual migraine care on work loss, productivity and patient preference. (IBA040) 2002

A randomized comparator, controlled, double blind study of the liver safety with XXXXX versus XXXXX as part of step therapy in subjects with Type 2 diabetes (ING002) 2001-2002

A randomized, double-blind, 9-month trial comparing bleeding patterns, persistency, patient assessments, and resource utilization of postmenopausal women receiving hormone replacement therapy within a managed care setting. (ING013) 2002

Safety and Immunogenicity of Tetanus and Diphtheria Toxoids Absorbed Combined with Component XXXXX Vaccine Compared to Tetanus and Diphtheria Toxoids Absorbed (Td) in Adolescents and Adults 11-64 Year of Age. (AVE006) 2001

A randomized, double-blind, dose-ranging, active-controlled trial to determine the safety and efficacy of XXXXX in patients with type 2 diabetes. (BMS026) 2001

A phase III, vehicle-controlled study of topical XXXXX applied 2 times per week for 1 week for each recurrence of anogenital herpes over 52 weeks. (3MP003) 2001

A comparison of XXXXX and XXXXX effect on BMD. (PUJ036) 2001

Prospective, Randomized, Double-Blind Multi-Center, Comparative Trial to Evaluate the Efficacy and Safety of XXXXX Once Daily Modified Release XXXXX 500 mg Tablets QD for 3 Days Versus Conventional XXXXX 250 mg Tablets BID for 3 Days in the Treatment of Patients with Uncomplicated Urinary Tract (UTI) Infections. (PHO003) 2001

Multi-center, open label study of the efficacy and safety drug in long-term care subjects with physician-diagnosed depression who are at least 70 years of age. (IBA030) 2001 

Birth Control, Phase III, 2000, Barr Labs Open label study of 3 month birth control pill 

A Randomized, Double-Blind, Active-Controlled Comparison of Study Drug and Comparator in Subjects with Newly Diagnosed or Established Hypertension. XXXXX Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE). (PPD099) 2000

Multicenter, double blind, double dummy, randomized study with a single-blind placebo baseline and wash out period. For patients 18 to 70 years of age (COV021) 2000

A 24 Week Randomized, Open Label Study of Health Care Resource Use, Quality of Life, and Productivity With XXXXX 1mg Twice Daily Versus Traditional Therapy in Females With Irritable Bowel Syndrome Whose Predominant Symptom is Diarrhea. (QUI018) 2000

Multicenter, randomized, placebo-controlled, double-blind, parallel arm pilot study to evaluate the efficacy of orally administered XXXXX in addition of standard therapy on clinical outcome parameters in adult out-patients with an acute exacerbation of chronic bronchitis. (98DPC01) 1999

Comparison of the Pharmacokinetics and Safety of XXXXX versus Orally Administered Reglan in Patients with Diabetic Gastroparesis. (GLO001) 1999

Rhinovirus, Phase III 1999

Asthma, Phase IV, 1998

Herpes Genitalis, Phase III, 1998

Chronic Bronchitis, Phase II, 1998

Streptococcal Pharyngitis, Phase III, 1997

Herpes Labialis, Phase II, 1997

Skin Infection, Phase II, 1997

NIDDM, Phase IV, 1995

CHF, Phase IV, 1994


Clin Infect Dis 2001 Oct 1;33(7):1076-9 (ISSN: 1058-4838)
Marovich MA; Lira R; Shepard M; Fuchs GH; Kruetzer R; Nutman TB; Neva FA
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA